Treatment of Enterococcus Faecalis Bacterem

Impact on Mortality of the Choice Between a Mono- Versus Combination Antibiotic Therapy in Enterococcus Faecalis Bacteremia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07299539

Acronym

E-faecalis

Enrollment

700

Registered

2025-12-23

Start date

2024-02-24

Completion date

2025-12-31

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enterococcus Faecalis Bacteremia

Keywords

Enterococcus faecalis bacteremia, Mortality, Monotherapy versus combination therapy

Brief summary

Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of simple Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Subject of legal age (≥18 years) * Having a positive blood culture result for Enterococcus faecalis identified within the microbiology laboratory of the University Hospital of Strasbourg during the period from 01 January 2017 to 31 December 2023.

Exclusion criteria

* Penicillin treatment \< 7 days * Treatment not containing a penicillin effective against enterococci among those studied: amoxicillin or piperacillin-tazobactam * Combination of penicillin with another antibiotic effective against enterococci other than cephalosporins or aminoglycosides (glycopeptides, linezolids, carbapenems, levofloxacin, moxifloxacin). * Bacteremia with one or more other pathogens within the first 7 days of bacteremia * Infective endocarditis at diagnosis and within the first 7 effective days of treatment * Resistance of Enterococcus faecalis to amoxicillin * Mortality \<72 hours after initiation of antibiotic therapy * Lack of information regarding the chosen antibiotic treatment

Design outcomes

Primary

Measure	Time frame
Intrahospital all-cause mortality	Up to 6 months

Countries

France

Contacts

Primary ContactYvon RUCH, MD

yvon.ruch@chru-strasbourg.fr33 3 69 55 12 1

Outcome results